Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Intermittent Claudication Market Growth Analysis: How Will Revenue Expand During The Forecast Period?
The market for intermittent claudication experienced robust expansion over recent years, projecting a value of $13.51 billion in 2025, set to increase to $14.31 billion by 2026, reflecting a compound annual growth rate of 5.9%. This growth trajectory during the historical period was influenced by several key factors, including the escalating occurrence of peripheral artery disease, a continually aging demographic, a significant number of vascular issues linked to smoking, the increasing burden of cardiovascular diseases, and the broader accessibility of vascular intervention techniques.
The market for intermittent claudication is poised for substantial expansion over the coming years, projecting a valuation of $17.98 billion by 2030 with a compound annual growth rate (CAGR) of 5.9%. This upward trajectory is anticipated to be fueled by heightened public understanding of peripheral artery disease symptoms, a burgeoning demand for less invasive vascular interventions, innovations in drug treatments, increased utilization of remote disease management strategies, and enhancements in screening and diagnostic methodologies. Key developments shaping the forecast period encompass a heightened emphasis on the early detection of peripheral artery disease, a greater inclination towards utilizing combination drug regimens, a growing shift towards outpatient revascularization procedures, the broadened availability of supervised exercise therapy, and enhanced patient education and self-management of the condition.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22021&type=smp
Intermittent Claudication Market Development Factors: Which Trends Are Supporting Demand?
The projected expansion of the intermittent claudication market is anticipated to be propelled by the rising incidence of peripheral artery disease (PAD), a condition characterized by constricted arteries that impede blood circulation to the extremities, resulting in discomfort, insensitivity, and potential health issues. This surge in PAD is linked to a confluence of factors, including an aging demographic, prevalent conditions like diabetes and hypertension, habits such as smoking, and lifestyle choices involving excessive weight and inactivity. PAD precipitates intermittent claudication by restricting oxygen supply to leg muscles during physical exertion, thereby inducing pain and spasms. To illustrate, data published in June 2023 by the American Heart Association Journals, a leading US-based scholarly publication, indicates that peripheral artery disease impacts between 7 and 12 million individuals in the United States and affects a staggering 200 million people worldwide, underscoring its role as a primary catalyst for the intermittent claudication market’s expansion.
Intermittent Claudication Market Segment Landscape And Growth Potential
The intermittent claudication market covered in this report is segmented –
1) By Type: Medication Therapies, Revascularization
2) By Route Of Administration: Parenteral Route, Oral Route, Other Routes Of Administration
3) By Application: Hospitals, Clinics, Home Healthcare, Other Applications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Medication Therapies: Antiplatelet Agents, Vasodilators, Phosphodiesterase Inhibitors, Cilostazol, Pentoxifylline
2) By Revascularization: Angioplasty, Stenting, Bypass Surgery, Endarterectomy
Intermittent Claudication Market Transformation Trends: Which Innovations Are Driving Change?
Within the market for intermittent claudication, key players are actively integrating cutting-edge, minimally invasive endovascular techniques, specifically percutaneous bypass systems, with the aim of boosting treatment effectiveness, increasing procedural success rates, and ultimately improving patient results. These sophisticated vascular technologies, known as percutaneous bypass systems, establish an endovascular bypass route through the use of specialized stent grafts and catheters. This innovation allows for the restoration of blood flow through extensive arterial blockages, thereby diminishing the necessity for traditional open surgical bypass procedures and facilitating quicker recuperation for patients. As an illustration of this advancement, in June of 2023, Endologix LLC, a prominent US entity dedicated to vascular disease therapies, secured FDA authorization for its DETOUR System. This particular system represents a pioneering, minimally invasive approach to percutaneous bypass, engineered to manage lengthy and intricate superficial femoropopliteal obstructions in individuals afflicted with peripheral artery disease (PAD). The DETOUR System incorporates the TORUS stent graft platform, which constitutes a novel endovascular bypass methodology, and possesses the capacity to tackle long arterial segment blockages, thereby offering an effective therapeutic avenue for formidable femoropopliteal occlusions. Consequently, the DETOUR System not only improves blood flow restoration but also curtails procedural complications and broadens the therapeutic choices available to patients experiencing symptomatic PAD and intermittent claudication.
Intermittent Claudication Market Competitive Landscape: Who Are The Leading Companies?
Major companies operating in the intermittent claudication market are Pfizer Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis AG, Teva Pharmaceutical, Otsuka Pharmaceutical Co. Ltd., Sanofi S.A., Bayer AG, Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories, Alkem Laboratories, Aastrid Life Sciences Pvt. Ltd., Manus Aktteva Biopharma LLP, Enomark Pharma.
Access The Complete Intermittent Claudication Market Report:
https://www.thebusinessresearchcompany.com/report/intermittent-claudication-global-market-report
Intermittent Claudication Market Leading Geography: Which Region Generates The Most Revenue?
North Americawas the largest region in the intermittent claudication market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the intermittent claudication market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model